In our first Roundtable event we explored how CD8 ImmunoPET may enhance decision making in early-stage clinical trials. In our second event, our panel of experts from multi-national pharmaceutical companies explored how CD8 ImmunoPET may help decision making through all phases of immunotherapy (IO) clinical trials.
The content within the recording of the Roundtable on the value that “CD8 ImmunoPET may offer in drug pipeline development in immunotherapy clinical trials” that took place on March 31st 2022, has been made available for informational and educational purposes only. This information is only available to pharmaceutical and biotech personnel working on projects related to IO clinical trials.
The efficacy and safety of ImaginAb’s investigational CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) discussed during the Roundtable event have not been established. There is no guarantee that these compounds will become commercially available for the use (or uses) under investigation.
Please find below the full recording of our engaging discussion with our expert panel: